Menstrual Cramps Treatment Market Expected to Reach $841.6 Million by 2031—Allied Market Research

According to a new report published by Allied Market Research, titled, “Menstrual Cramps Treatment Market," The menstrual cramps treatment market size was valued at $560.89 million in 2021, and is estimated to reach $841.6 million by 2031, growing at a CAGR of 4.1% from 2022 to 2031.

Dysmenorrhea is a medical term for menstrual cramps in which a woman feels severe cramps in her lower abdomen that can spread to her lower legs and back. It is a painful sensation that affects many people before and during a menstrual period. It has two types including primary dysmenorrhea and secondary dysmenorrhea.

Primary dysmenorrhea is pain that only occurs during menstruation and secondary dysmenorrhea is a period pain caused by a medical condition, such as endometriosis, uterine fibroids, or pelvic inflammatory disease. During menstruation, prostaglandins are chemicals that are secreted into the uterine lining. These prostaglandins cause painful uterine muscle contractions and reduce blood and oxygen flow to the uterus which causes menstrual cramps. Menstrual cramps are frequently relieved with over-the-counter pain relievers such as Ibuprofen and other nonsteroidal anti-inflammatory drugs (NSAIDs) can help with pain relief.

Menstrual cramps treatment market trends that drive growth of the market include rise in prevalence of dysmenorrhea caused due to environmental factors and changes in lifestyles along with unhealthy eating habits. For instance, according to a Journal published by the American College of Obstetricians and Gynecologists (ACOG), in 2021, the prevalence rate of dysmenorrhea rage from 50% to 90%.  

In addition, major players are investing in the development and commercialization of menstrual cramps treatment to decrease incidences of dysmenorrhea further fuel the growth during menstrual cramps treatment market analysis. On the other hand, side effects associated with drug treatment may hamper the market growth. For instance, naproxen drug used to reduce the menstrual cramps can cause bloating, drowsiness, nausea and vomiting. 

Moreover, rise in R&D activities for menstrual cramps drugs further boost the  growth menstrual cramps treatment market forecast. Moreover, rise in awareness among women regarding menstrual cramps treatment, is expected to propel the market growth. Furthermore, rise in prevalence of reproductive track anomalies which causes secondary dysmenorrhea is expected to propel the market growth during the forecast period. For instance, according to a journal published by American College of Obstetricians and Gynecologists (ACOG), in 2021, the estimated occurrence of reproductive track anomalies is 0.1-3.8% of young women.

On the basis of type, the market is bifurcated into primary dysmenorrhea and secondary dysmenorrhea. The primary dysmenorrhea segment exhibited highest menstrual cramps treatment market share in 2021, and is expected to remain dominant during the forecast period, owing to rise in prevalence of primary dysmenorrhea. In addition, rise in depression and anxiety, attempts to lose weight are the factors responsible to cause primary dysmenorrhea and further drive the segment growth.

On the basis of treatment, the market is segmented into non-steroidal anti-inflammatory drugs and hormonal therapy. The non-steroidal anti-inflammatory drugs exhibited highest growth in 2021, and is expected to remain dominant during the forecast period, owing to high adoption of non-steroidal anti-inflammatory drugs due to rise in prevalence of primary and secondary dysmenorrhea.

On the basis of distribution channel, the market is classified into hospital pharmacies, drug stores & retail pharmacies and online providers. The drug stores & retail pharmacies dominated the menstrual cramps treatment industry in 2021, owing to it provide better financial and debt management to patients. Moreover, the online providers segment is projected to register a highest CAGR during the forecast period, owing to availability of a menstrual cramp drugs such as ibuprofen and naproxen sodium on e-commerce platforms is more than pharmacies/retail stores, which helps patients buy products at ease.

Region wise, North America held the highest menstrual cramps treatment market share in 2021, and is expected to maintain its lead during the forecast period, owing to increase in demand for menstrual cramps treatment due to rise in prevalence of dysmenorrhea. In addition, rise in awareness regrading menstrual cramps treatment in this region boost the market growth. However, Asia-Pacific is anticipated to register the highest CAGR during the forecast period, owing to increase in health awareness and rise in number of hospitals equipped with advanced medical facilities.

Key findings of the study
• By type, the primary dysmenorrhea segment was highest contributor to the menstrual cramps treatment industry in 2021.
• On the basis of treatment, the non-steroidal anti-inflammatory drugs segment was dominated the market in 2021. 
• By distribution channel, the drug stores & retail pharmacies segment dominated the market in 2021. However, online providers segment is anticipated to grow at the highest CAGR of during the forecast period.
• Region wise, North America generated the largest revenue in the menstrual cramps treatment market size in 2021. However, Asia-Pacific is anticipated to grow at the highest CAGR of during the forecast period.